The note repurchases reduce potential dilution from conversion, a modest positive for equity holders. Watch for announcement of replacement debt financing, which could alter leverage. The second tranche closes by July 30, monitor for any adjustments based on stock price during the averaging period.
OMER drugs
OMER drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 6 $10.34entry
- T+1 · 4mo ago −0.10%α +0.38% · $10.33
- T+5 · 4mo ago −0.58%α −1.07% · $10.28
- T+20 · 4mo ago +14.51%α +15.07% · $11.84
- T+60 · 7w ago +86.17%α +84.45% · $19.25
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Omeros disclosed the completion of a $16.0M principal repurchase of its 9.50% Convertible Senior Notes due 2029 for ~$31.3M, and entered new agreements to repurchase up to an additional $14.5M principal for up to ~$31.0M. These transactions reduce convertible debt overhang and potential dilution, but consume significant cash that may be replaced with non-convertible debt.
Key Facts
- Completed repurchase of $16.0M aggregate principal amount of 9.50% Convertible Senior Notes due 2029 for ~$31.3M total, leaving $54.8M outstanding.
- Entered new agreements to repurchase up to ~$14.5M additional principal for up to ~$31.0M, expected to close July 20–30, 2026.
- If fully executed, ~$40.3M aggregate principal of Notes will remain outstanding.
- Company may replace cash used with unsecured or limited-collateral debt not convertible into equity.
Financial Impact
Total cash outlay of up to ~$62.3M for both tranches, representing ~9.3% of market cap ($672M). Reduces convertible debt from ~$71.3M to ~$40.3M.
Risk Factors
- Cash depletion of ~$62.3M may pressure liquidity if not replaced with new debt.
- New non-convertible debt could increase leverage and interest expense.
- Repurchase premium (~2x principal) reflects significant cost to retire the notes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001552781-26-000377 |
| Document: 0001552781-26-000377-index-headers.html | 0001552781-26-000377 |
| Document: 0001552781-26-000377-index.html | 0001552781-26-000377 |
| Document: 0001552781-26-000377.txt | 0001552781-26-000377 |
Track record
12 reports on OMER
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +98.11% at T+60 after the Jul 20, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $16.92 Now $16.68 −1.42% settles Feb 4
- Oct 30, 202617d ago 8-K Neutral 3/10 Entry $17.83 Now $16.68 −6.45% settles Jan 29
- Sep 1, 202610w ago Insider Cluster Neutral 2/10 Entry $18.86 Now $16.68 −11.56% settles Nov 27
- Aug 28, 202611w ago Insider Cluster Neutral Not scored Entry $18.79 Now $16.68 −11.23% settles Nov 24
- Aug 25, 202611w ago Insider Cluster Neutral 3/10 Entry $18.22 Now $16.68 −8.45% settles Nov 19
- Aug 21, 202612w ago Insider Cluster Neutral 2/10 Entry $19.32 Now $16.68 −13.66% settles Nov 17
- Jul 20, 202617w ago 8-K Bullish 5/10 Entry $9.53 to $18.88 Now $16.68 +75.03% ▲ +98.11% +94.14% vs SPY
- Jul 6, 202619w ago 8-K Neutral 4/10 Viewing Entry $10.34 to $19.25 Now $16.68 +61.32% ▲ +86.17% +84.45% vs SPY
- Jun 18, 202621w ago 8-K Bullish 5/10 Entry $10.28 to $17.46 Now $16.68 +62.26% ▲ +69.84% +67.95% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 4/10 Entry $10.18 to $18.95 Now $16.68 +63.85% ▲ +86.15% +81.75% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers